Year: 2023
Type: article
Abstract: Landmark SELECT Trial Shows Exciting Results: Will Semaglutide be the Game Changer in Obesity Management?Use of semaglutide 2.4 mg reduced the risk of major adverse cardiovascular (CV) events in patients with overweight or obesity and known cardiovascular disease (CVD) but no diabetes by 20%, according to headline results from the landmark Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) CV outcomes trial (CVOT), released early this week.The trial involved participants across a wide range of clinically relevant risk categories.According to the top-line results, a 20% reduction in the incidence of composite of major adverse cardiovascular event (MACE) was noted in patients treated with semaglutide compared with placebo, which was statistically significant.All the three components of MACE contributed to the decline with MACE seen with semaglutide.Moreover, it was also safe and welltolerated.
Author: IJCP Group
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7050768619
